IS5085A - Nefholssamsetningar til meðhöndlunar á kynferðistruflunum - Google Patents

Nefholssamsetningar til meðhöndlunar á kynferðistruflunum

Info

Publication number
IS5085A
IS5085A IS5085A IS5085A IS5085A IS 5085 A IS5085 A IS 5085A IS 5085 A IS5085 A IS 5085A IS 5085 A IS5085 A IS 5085A IS 5085 A IS5085 A IS 5085A
Authority
IS
Iceland
Prior art keywords
treatment
sexual disorders
conjunctiva
nasal
nasal conjunctiva
Prior art date
Application number
IS5085A
Other languages
English (en)
Inventor
Billotte Anne
James Dunn Peter
Thomas Henry Brian
Vallance Marshall Peter
Jayne Woods Joanna
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813452.1A external-priority patent/GB9813452D0/en
Priority claimed from GBGB9820837.4A external-priority patent/GB9820837D0/en
Priority claimed from GBGB9903177.5A external-priority patent/GB9903177D0/en
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of IS5085A publication Critical patent/IS5085A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS5085A 1998-06-22 1999-06-18 Nefholssamsetningar til meðhöndlunar á kynferðistruflunum IS5085A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9813452.1A GB9813452D0 (en) 1998-06-22 1998-06-22 Pharmaceutical formulations
GBGB9820837.4A GB9820837D0 (en) 1998-09-24 1998-09-24 Pharmaceutical formulations
GBGB9903177.5A GB9903177D0 (en) 1999-02-13 1999-02-13 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
IS5085A true IS5085A (is) 1999-12-23

Family

ID=27269368

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5085A IS5085A (is) 1998-06-22 1999-06-18 Nefholssamsetningar til meðhöndlunar á kynferðistruflunum

Country Status (40)

Country Link
US (2) US20020040139A1 (is)
EP (1) EP0967214B1 (is)
JP (1) JP3263379B2 (is)
KR (1) KR100345824B1 (is)
AP (1) AP1178A (is)
AR (1) AR016993A1 (is)
AT (1) ATE269866T1 (is)
AU (1) AU746865B2 (is)
BG (1) BG64372B1 (is)
BR (1) BR9903273A (is)
CA (1) CA2275554C (is)
CZ (1) CZ294856B6 (is)
DE (1) DE69918222T2 (is)
DK (1) DK0967214T3 (is)
DZ (1) DZ2826A1 (is)
EA (1) EA001903B1 (is)
ES (1) ES2221733T3 (is)
GT (1) GT199900095A (is)
HN (1) HN1999000096A (is)
HR (1) HRP990195B1 (is)
HU (1) HUP9902076A3 (is)
ID (1) ID23554A (is)
IL (1) IL130539A0 (is)
IS (1) IS5085A (is)
MA (1) MA25089A1 (is)
MY (1) MY117967A (is)
NO (1) NO317365B1 (is)
NZ (1) NZ336382A (is)
OA (1) OA11069A (is)
PA (1) PA8476301A1 (is)
PE (1) PE20000702A1 (is)
PT (1) PT967214E (is)
SG (1) SG77246A1 (is)
SI (1) SI0967214T1 (is)
SK (1) SK284574B6 (is)
TN (1) TNSN99129A1 (is)
TR (1) TR199901444A2 (is)
TW (1) TWI223598B (is)
UA (1) UA59385C2 (is)
YU (1) YU29699A (is)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
EP1237538A2 (en) * 1999-11-18 2002-09-11 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
AU2002310086B2 (en) * 2001-05-24 2008-09-04 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US7138107B2 (en) * 2003-02-18 2006-11-21 Compellis Pharmaceuticals Inhibition of olfactory neurosensory function to treat eating disorders and obesity
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
WO2004104490A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1785145A4 (en) * 2004-08-10 2008-08-13 Translational Res Ltd TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
EP1802277B1 (de) 2004-10-18 2010-01-13 Polymun Scientific Immunbiologische Forschung GmbH Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung
WO2006094924A2 (en) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
ME01609B (me) 2005-04-19 2014-09-20 Takeda Gmbh Roflumilast za liječenje pulmonarne hipertenzije
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
WO2007027612A2 (en) * 2005-08-29 2007-03-08 Teva Pharmaceutical Industries Ltd. Solid particulate tadalafil having a bimodal particle size distribution
GB0526283D0 (en) * 2005-12-23 2006-02-01 Givaudan Sa Compositions
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
EP2116264B1 (en) * 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DE102008004893A1 (de) * 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
US20110033506A1 (en) * 2008-02-08 2011-02-10 Adel Penhasi Combination dosage form of low-dose modafinil and low-dose sildenafil
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
KR101306537B1 (ko) 2008-06-04 2013-09-09 콜게이트-파아므올리브캄파니 캐비테이션 시스템을 가진 구강 관리기구
WO2009152344A2 (en) * 2008-06-11 2009-12-17 Comgenrx, Inc. Combination therapy using phosphodiesterase inhibitors
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
JP2011001317A (ja) * 2009-06-19 2011-01-06 Fumakilla Ltd 鼻用洗浄剤
US8827946B2 (en) * 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
EP2568968B1 (en) 2010-05-10 2017-07-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
ES2917973T3 (es) 2011-06-14 2022-07-12 Neurelis Inc Administración de benzodiacepina
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
WO2014055801A1 (en) * 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
CA2795324C (en) * 2012-11-09 2015-07-14 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
RU2536425C2 (ru) * 2013-01-17 2014-12-20 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция, содержащая силденафил цитрат, и способ ее приготовления
WO2014143453A1 (en) * 2013-03-15 2014-09-18 Henkin Robert I Phosphodiesterase inhibitor treatment
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
EP3108245B1 (en) 2014-02-18 2020-07-22 Robert I. Henkin Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
NO2723977T3 (is) 2014-03-19 2018-03-10
WO2017024029A1 (en) * 2015-08-03 2017-02-09 Synergistic Therapeutics, Llc Sexual dysfunction therapeutic gel
MX2019004894A (es) * 2016-10-31 2019-06-20 Suda Ltd Administración de agente activo de la mucosa.
ES2880474T3 (es) 2017-03-02 2021-11-24 Dutch Renewable Energy B V Administración intranasal de sustancias fisiológicamente activas
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN111683683A (zh) 2017-12-26 2020-09-18 Ftf药业私人有限公司 Pde v抑制剂的液体口服制剂
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
CA3097077A1 (en) * 2018-04-16 2019-10-24 Barista Mist Pty Ltd Caffeine compositions and methods of use
SE542968C2 (en) * 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
US20220111162A1 (en) * 2020-07-29 2022-04-14 Lido Ventures Llc Apparatus, system, and method for facilitating intranasal treatment of a patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
NZ323571A (en) * 1995-11-20 1998-12-23 Lilly Co Eli Protein kinase c inhibitor
BR9809508A (pt) * 1997-05-29 2000-06-20 Mochida Pharm Co Ltd Agente terapêutico para disfunção de ereção
JP4754067B2 (ja) * 1997-12-02 2011-08-24 アルキメデス ディヴェロプメント リミテッド 鼻孔投与用組成物
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
HRP990195B1 (en) 2003-04-30
AP9901585A0 (en) 1999-06-30
BR9903273A (pt) 2000-05-09
TWI223598B (en) 2004-11-11
KR100345824B1 (ko) 2002-07-24
AU746865B2 (en) 2002-05-02
PA8476301A1 (es) 2000-09-29
YU29699A (sh) 2003-02-28
JP3263379B2 (ja) 2002-03-04
PE20000702A1 (es) 2000-08-16
ATE269866T1 (de) 2004-07-15
BG64372B1 (bg) 2004-12-30
CA2275554A1 (en) 1999-12-22
SI0967214T1 (en) 2004-10-31
CZ294856B6 (cs) 2005-03-16
EA199900487A3 (ru) 2000-04-24
HUP9902076A3 (en) 2002-03-28
SK81999A3 (en) 2001-01-18
NZ336382A (en) 1999-11-29
MY117967A (en) 2004-08-30
TNSN99129A1 (fr) 2005-11-10
NO993051L (no) 1999-12-23
CZ9902257A3 (cs) 2000-11-15
JP2000034232A (ja) 2000-02-02
EP0967214B1 (en) 2004-06-23
DE69918222D1 (de) 2004-07-29
IL130539A0 (en) 2000-06-01
HRP990195A2 (en) 2000-02-29
BG103510A (en) 2000-01-31
CA2275554C (en) 2003-06-03
EA001903B1 (ru) 2001-10-22
NO317365B1 (no) 2004-10-18
DE69918222T2 (de) 2005-07-28
ES2221733T3 (es) 2005-01-01
SG77246A1 (en) 2000-12-19
DZ2826A1 (fr) 2003-12-01
KR20000006310A (ko) 2000-01-25
GT199900095A (es) 2000-12-13
ID23554A (id) 2000-05-04
US20020040139A1 (en) 2002-04-04
OA11069A (en) 2002-03-13
NO993051D0 (no) 1999-06-21
EP0967214A1 (en) 1999-12-29
UA59385C2 (uk) 2003-09-15
HUP9902076A2 (hu) 2000-05-28
HN1999000096A (es) 2000-12-03
MA25089A1 (fr) 2000-12-31
HU9902076D0 (en) 1999-08-30
TR199901444A2 (xx) 2000-01-21
DK0967214T3 (da) 2004-09-27
PT967214E (pt) 2004-08-31
AU3579499A (en) 2000-01-06
SK284574B6 (sk) 2005-06-02
AP1178A (en) 2003-06-30
EA199900487A2 (ru) 1999-12-29
AR016993A1 (es) 2001-08-01
US20030158206A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
IS5085A (is) Nefholssamsetningar til meðhöndlunar á kynferðistruflunum
IS2494B (is) Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
ID30276A (id) Metode untuk mengobati gangguan-gangguan seksual
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
IS7941A (is) Bensasepínafleiður til að meðhöndla taugasjúkdóma
DK2052714T3 (da) Topisk gel-fremføringssystem til behandling af hudlidelser
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
NO20026263L (no) Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser
NO20005884L (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
NO20041386L (no) Kombinasjoner for bahandling av immunoinflammatoriske forstyrrelser
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
IS6137A (is) Meðhöndlun á hugsýkistruflunum
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
DK1309322T3 (da) Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
IS4569A (is) Bensamíð til að meðhöndla taugahrörnunarsjúkdóma
DK1121356T3 (da) 3-tetrahydropyridin-4-yl-indoler til behandling af psykotiske lidelser
PT1294710E (pt) Derivados de indole uteis para o tratamento de disturbios do snc
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
HUP0102886A3 (en) Treatment of anxiety disorders
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
NO20030717D0 (no) Forbindelser for behandling av avhengighetsforstyrrelser
IS6619A (is) S-metýl-díhýdró-siprasídón til meðhöndlunar á geðrænum kvillum og augnkvillum